• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Nexalin Technology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    6/9/25 5:19:30 PM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NXL alert in real time by email
    false 0001527352 0001527352 2025-06-06 2025-06-06 0001527352 nxl:CommonStockParValue0.001PerShareMember 2025-06-06 2025-06-06 0001527352 nxl:WarrantsEachExercisableForOneShareOfCommonStockMember 2025-06-06 2025-06-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): June 6, 2025

     

    NEXALIN TECHNOLOGY, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41507   27-5566468
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    1776 Yorktown, Suite 550

    Houston, TX 77056

    Registrant’s telephone number, including area code: (832) 260-0222

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   NXL   The Nasdaq Stock Market LLC
             
    Warrants, each exercisable for one share of Common Stock   NXLIW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

     

     

     

       

     

     

    Item 8.01. Other Events.

     

    As previously reported on a Current Report on Form 8-K filed by Nexalin Technology, Inc. (the “Company”) with the U.S. Securities and Exchange Commission on May 6, 2025, on May 4, 2025, the Company entered into an underwriting agreement with Maxim Group LLC (the “Representative”), pursuant to which the Company agreed to sell to the Representative, in a firm commitment public offering, 3,850,000 shares of the Company’s common stock, par value $0.001 per share, for a public offering price of $1.30 per share. The Company also granted the Representative a 45-day over-allotment option to purchase up to 577,500 shares of the Company’s common stock (the “Option Shares”).

     

    On June 5, 2025, the Representative partially exercised its option, and on June 6, 2025, the Company closed the offering of 240,000 of the Option Shares to the Representative, at a price of $1.30 per share, for aggregate gross proceeds of $312,000, less applicable underwriter discounts.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit   Description
    104   Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document)

     

     1 

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report on form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

     

      NEXALIN TECHNOLOGY, INC.
       
      By: /s/ Mark White
        Mark White
        Chief Executive Officer

     

    Dated: June 9, 2025

     

     2 
    Get the next $NXL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NXL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NXL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      3/13/25 4:52:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by President and CEO White Mark

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/27/25 4:34:13 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Owens David

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      2/27/25 4:33:38 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care